Edgar Filing: AERIE PHARMACEUTICALS INC - Form 4

AERIE PHARMACEUTICA Form 4 June 13, 2014	LS INC							
Check this box if no longer subject to Section 16. Form 4 or Form 5 chligations	MENT OF Cl rsuant to Secti (a) of the Publ	CURITIES AND F Washington, D.C. HANGES IN BENI SECURITIE ion 16(a) of the Secu lic Utility Holding C the Investment Comp	20549 EFICIAL OV S urities Exchar Company Act	WNERSHIP OF nge Act of 1934, of 1935 or Sectio	N OMB Number: Expires: Estimated burden hou response	urs per		
(Print or Type Responses)								
1. Name and Address of Reporting DUYK GEOFFREY M	Syn AE	Issuer Name and Ticker nbol ERIE PHARMACEU ERI]	-	5. Relationship o Issuer C (Che	of Reporting Per			
(Last) (First) (C/O TPG GLOBAL, LLC,, 3 COMMERCE STREET, SU 3300	(Mo 301 06/	Date of Earliest Transacti onth/Day/Year) /11/2014	on	X Director Officer (giv below)		% Owner her (specify		
(Street)		4. If Amendment, Date Original 6. Individual or Join Filed(Month/Day/Year) Applicable Line) _X_ Form filed by Or			One Reporting P			
FORT WORTH, TX 76102				Form filed by Person	More than One R	eporting		
(City) (State)	(Zip)	Table I - Non-Derivat	ive Securities A	cquired, Disposed o	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date any (Month/Day/Ye	3.4. Sectore, ifTransactionAcquirCodeDispose	urities red (A) or sed of (D) 3, 4 and 5) (A) or	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Reminder: Report on a separate line	e for each class o	of securities beneficially	owned directly of	or indirectly.				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

	1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S (
					Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
	Option (right to buy)	\$ 17.55	06/11/2014		A	13,500	<u>(1)</u>	06/11/2024	Common Stock	13,500	
Reporting Owners											

Reporting Owner Name / Address	Relationships				
13	Director	10% Owner	Officer	Other	
DUYK GEOFFREY M C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300 FORT WORTH, TX 76102	Х				
Signatures					
By: Ronald Cami on behalf of Geoffrey M					

By: Ronald Cami on behalf of Geoffrey M. Duyk (2)	06/13/2014
<u>**Signature of Reporting Person</u>	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option will be fully vested on June 11, 2015, subject to the director's continued service on the board of directors of Aerie Pharmaceuticals, Inc. through such date.

Remarks:

(2)Ronald Cami is signing on behalf of Dr. Duyk pursuant to the authorization and designation letter dated July 1, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

8 E S